US Bancorp DE Sells 174,295 Shares of Kenvue Inc. $KVUE

US Bancorp DE reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 54.0% during the third quarter, Holdings Channel reports. The firm owned 148,440 shares of the company’s stock after selling 174,295 shares during the period. US Bancorp DE’s holdings in Kenvue were worth $2,409,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KVUE. AlphaCore Capital LLC boosted its stake in shares of Kenvue by 9.9% in the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock worth $111,000 after buying an additional 476 shares during the last quarter. Empirical Finance LLC grew its stake in Kenvue by 1.8% in the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after purchasing an additional 491 shares during the period. J.W. Cole Advisors Inc. increased its position in shares of Kenvue by 3.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock valued at $324,000 after purchasing an additional 574 shares during the last quarter. Spire Wealth Management raised its stake in shares of Kenvue by 13.5% during the 2nd quarter. Spire Wealth Management now owns 4,863 shares of the company’s stock worth $102,000 after purchasing an additional 580 shares during the period. Finally, Versor Investments LP boosted its holdings in shares of Kenvue by 2.8% in the 3rd quarter. Versor Investments LP now owns 26,016 shares of the company’s stock worth $422,000 after buying an additional 716 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 3.8%

Shares of NYSE:KVUE opened at $18.17 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a market cap of $34.83 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 4.33 and a beta of 0.51. The firm has a fifty day moving average price of $17.78 and a two-hundred day moving average price of $17.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.22 by $0.05. The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.26 earnings per share. Analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s payout ratio is 107.79%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Canaccord Genuity Group raised their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Barclays increased their price target on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Finally, Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $19.50.

Insider Buying and Selling

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director owned 27,307,632 shares in the company, valued at $474,333,567.84. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is owned by company insiders.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.